Cargando…

Somatostatin-receptor scintigraphy for staging and follow-up of patients with extraintestinal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT)-type

The majority of lymphomas of the mucosa-associated lymphoid tissue (MALT)-type arise in the stomach, but extragastric locations are also frequently encountered. Due to previous results indicating that somatostatin receptor (SSTR)-expression distinguishes between gastric and extragastric MALT-type ly...

Descripción completa

Detalles Bibliográficos
Autores principales: Raderer, M, Traub, T, Formanek, M, Virgolini, I, Österreicher, C, Fiebiger, W, Penz, M, Jäger, U, Pont, J, Chott, A, Kurtaran, A
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2001
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363931/
https://www.ncbi.nlm.nih.gov/pubmed/11720429
http://dx.doi.org/10.1054/bjoc.2001.2070
_version_ 1782153827591389184
author Raderer, M
Traub, T
Formanek, M
Virgolini, I
Österreicher, C
Fiebiger, W
Penz, M
Jäger, U
Pont, J
Chott, A
Kurtaran, A
author_facet Raderer, M
Traub, T
Formanek, M
Virgolini, I
Österreicher, C
Fiebiger, W
Penz, M
Jäger, U
Pont, J
Chott, A
Kurtaran, A
author_sort Raderer, M
collection PubMed
description The majority of lymphomas of the mucosa-associated lymphoid tissue (MALT)-type arise in the stomach, but extragastric locations are also frequently encountered. Due to previous results indicating that somatostatin receptor (SSTR)-expression distinguishes between gastric and extragastric MALT-type lymphoma, we have initiated a study to evaluate the role of SSTR-scintigraphy for staging and follow-up of patients with extragastric manifestations of MALT-type lymphoma. A total of 30 consecutive patients, including 24 with primary extragastric MALT-type lymphoma, 5 patients with dissemination to extragastric sites (including colon, lung, parotid, ocular adnexa and breast) following an initial gastric MALT-lymphoma and one patient with spread to stomach, lung and lymph nodes following parotid lymphoma were prospectively studied. All patients had histologically verified MALT-type lymphoma: 2 patients had lymphoma presenting in the lung, 9 in the ocular adnexa, 7 had lymphomas in the parotid, 2 patients had disease located in the breast, 3 patients had lymph-node relapse following MALT-type lymphoma of the parotid, the lacrimal gland and the thyroid, and 1 had primary MALT-lymphoma of the liver. All patients underwent SSTR-scintigraphy using (111)In-DTPA-D-Phe(1)-Octreotide ((111)In-OCT) before initiation of therapy, while 13 also had a second scan after treatment. The results of gamma camera imaging were compared to conventional staging. No positive scans could be obtained in patients with dissemination following gastric lymphoma, while all patients with primary extragastric lymphoma had positive scans at the site of histologically documented involvement before initiation of therapy. In addition, also the patient with secondary spread to stomach, lung and lymph nodes was positive in all documented lymphoma sites. In one patient, focal tracer uptake in projection to the maxillary sinus was documented, which was bioptically verified as inflammation. In the scans performed after therapy, focal tracer accumulation in the left orbit indicated persistance of disease following irradiation in one patient with otherwise negative work-up, which was verified by MRI and biopsy 6 months later. In another patient, a positive scan indicated disease relapse in the lacrimal gland 9 months before clinical verification by means of ultrasound. In one patient, a focus not present in the pretherapeutic scan was found in the ethmoidal sinus, corresponding to a hyperplastic polyp. Both SST-scan as well as CT indicated disease persistance in one case, while negative scans corresponding to complete remission as judged by conventional staging were obtained following therapy in the remaining patients, and absence of relapse has been confirmed for a median follow-up of 2 years. These results indicate that (111)In-OCT is an excellent tool for staging and non-invasive therapy-monitoring in extragastric MALT-type lymphomas. These data further confirm our initial finding that gastric MALT-type lymphomas do not express relevant amounts of respective SSTR, and that SSTR-scanning is able to distinguish between gastric vs extragastric origin of MALT-type lymphoma irrespective of the site of presentation.© 2001 Cancer Research Campaign  http://www.bjcancer.com
format Text
id pubmed-2363931
institution National Center for Biotechnology Information
language English
publishDate 2001
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-23639312009-09-10 Somatostatin-receptor scintigraphy for staging and follow-up of patients with extraintestinal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT)-type Raderer, M Traub, T Formanek, M Virgolini, I Österreicher, C Fiebiger, W Penz, M Jäger, U Pont, J Chott, A Kurtaran, A Br J Cancer Regular Article The majority of lymphomas of the mucosa-associated lymphoid tissue (MALT)-type arise in the stomach, but extragastric locations are also frequently encountered. Due to previous results indicating that somatostatin receptor (SSTR)-expression distinguishes between gastric and extragastric MALT-type lymphoma, we have initiated a study to evaluate the role of SSTR-scintigraphy for staging and follow-up of patients with extragastric manifestations of MALT-type lymphoma. A total of 30 consecutive patients, including 24 with primary extragastric MALT-type lymphoma, 5 patients with dissemination to extragastric sites (including colon, lung, parotid, ocular adnexa and breast) following an initial gastric MALT-lymphoma and one patient with spread to stomach, lung and lymph nodes following parotid lymphoma were prospectively studied. All patients had histologically verified MALT-type lymphoma: 2 patients had lymphoma presenting in the lung, 9 in the ocular adnexa, 7 had lymphomas in the parotid, 2 patients had disease located in the breast, 3 patients had lymph-node relapse following MALT-type lymphoma of the parotid, the lacrimal gland and the thyroid, and 1 had primary MALT-lymphoma of the liver. All patients underwent SSTR-scintigraphy using (111)In-DTPA-D-Phe(1)-Octreotide ((111)In-OCT) before initiation of therapy, while 13 also had a second scan after treatment. The results of gamma camera imaging were compared to conventional staging. No positive scans could be obtained in patients with dissemination following gastric lymphoma, while all patients with primary extragastric lymphoma had positive scans at the site of histologically documented involvement before initiation of therapy. In addition, also the patient with secondary spread to stomach, lung and lymph nodes was positive in all documented lymphoma sites. In one patient, focal tracer uptake in projection to the maxillary sinus was documented, which was bioptically verified as inflammation. In the scans performed after therapy, focal tracer accumulation in the left orbit indicated persistance of disease following irradiation in one patient with otherwise negative work-up, which was verified by MRI and biopsy 6 months later. In another patient, a positive scan indicated disease relapse in the lacrimal gland 9 months before clinical verification by means of ultrasound. In one patient, a focus not present in the pretherapeutic scan was found in the ethmoidal sinus, corresponding to a hyperplastic polyp. Both SST-scan as well as CT indicated disease persistance in one case, while negative scans corresponding to complete remission as judged by conventional staging were obtained following therapy in the remaining patients, and absence of relapse has been confirmed for a median follow-up of 2 years. These results indicate that (111)In-OCT is an excellent tool for staging and non-invasive therapy-monitoring in extragastric MALT-type lymphomas. These data further confirm our initial finding that gastric MALT-type lymphomas do not express relevant amounts of respective SSTR, and that SSTR-scanning is able to distinguish between gastric vs extragastric origin of MALT-type lymphoma irrespective of the site of presentation.© 2001 Cancer Research Campaign  http://www.bjcancer.com Nature Publishing Group 2001-11 /pmc/articles/PMC2363931/ /pubmed/11720429 http://dx.doi.org/10.1054/bjoc.2001.2070 Text en Copyright © 2001 Cancer Research Campaign https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Regular Article
Raderer, M
Traub, T
Formanek, M
Virgolini, I
Österreicher, C
Fiebiger, W
Penz, M
Jäger, U
Pont, J
Chott, A
Kurtaran, A
Somatostatin-receptor scintigraphy for staging and follow-up of patients with extraintestinal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT)-type
title Somatostatin-receptor scintigraphy for staging and follow-up of patients with extraintestinal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT)-type
title_full Somatostatin-receptor scintigraphy for staging and follow-up of patients with extraintestinal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT)-type
title_fullStr Somatostatin-receptor scintigraphy for staging and follow-up of patients with extraintestinal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT)-type
title_full_unstemmed Somatostatin-receptor scintigraphy for staging and follow-up of patients with extraintestinal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT)-type
title_short Somatostatin-receptor scintigraphy for staging and follow-up of patients with extraintestinal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT)-type
title_sort somatostatin-receptor scintigraphy for staging and follow-up of patients with extraintestinal marginal zone b-cell lymphoma of the mucosa associated lymphoid tissue (malt)-type
topic Regular Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363931/
https://www.ncbi.nlm.nih.gov/pubmed/11720429
http://dx.doi.org/10.1054/bjoc.2001.2070
work_keys_str_mv AT radererm somatostatinreceptorscintigraphyforstagingandfollowupofpatientswithextraintestinalmarginalzonebcelllymphomaofthemucosaassociatedlymphoidtissuemalttype
AT traubt somatostatinreceptorscintigraphyforstagingandfollowupofpatientswithextraintestinalmarginalzonebcelllymphomaofthemucosaassociatedlymphoidtissuemalttype
AT formanekm somatostatinreceptorscintigraphyforstagingandfollowupofpatientswithextraintestinalmarginalzonebcelllymphomaofthemucosaassociatedlymphoidtissuemalttype
AT virgolinii somatostatinreceptorscintigraphyforstagingandfollowupofpatientswithextraintestinalmarginalzonebcelllymphomaofthemucosaassociatedlymphoidtissuemalttype
AT osterreicherc somatostatinreceptorscintigraphyforstagingandfollowupofpatientswithextraintestinalmarginalzonebcelllymphomaofthemucosaassociatedlymphoidtissuemalttype
AT fiebigerw somatostatinreceptorscintigraphyforstagingandfollowupofpatientswithextraintestinalmarginalzonebcelllymphomaofthemucosaassociatedlymphoidtissuemalttype
AT penzm somatostatinreceptorscintigraphyforstagingandfollowupofpatientswithextraintestinalmarginalzonebcelllymphomaofthemucosaassociatedlymphoidtissuemalttype
AT jageru somatostatinreceptorscintigraphyforstagingandfollowupofpatientswithextraintestinalmarginalzonebcelllymphomaofthemucosaassociatedlymphoidtissuemalttype
AT pontj somatostatinreceptorscintigraphyforstagingandfollowupofpatientswithextraintestinalmarginalzonebcelllymphomaofthemucosaassociatedlymphoidtissuemalttype
AT chotta somatostatinreceptorscintigraphyforstagingandfollowupofpatientswithextraintestinalmarginalzonebcelllymphomaofthemucosaassociatedlymphoidtissuemalttype
AT kurtarana somatostatinreceptorscintigraphyforstagingandfollowupofpatientswithextraintestinalmarginalzonebcelllymphomaofthemucosaassociatedlymphoidtissuemalttype